| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
SZL P1-41 is a Skp2 inhibitor that phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival, Akt-mediated glycolysis as well as triggering p53-independent cellular senescence.The reference concentration is 5 uM. SZL P1-41 restricts cancer cell survival through triggering p53-independent cellular senescence and inhibiting aerobic glycolysis. SZL P1-41 exhibits potent anti-tumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival.
| Targets |
Skp2
|
||
|---|---|---|---|
| ln Vitro |
In PC3 cells, SZL P1-41 (5–20μM; 24 hours) stimulates the expression of p21, another Skp2 substrate, as well as endogenous p27 protein[1].
|
||
| ln Vivo |
SZL P1-41 (40–80 mg/kg; i.p.) has a strong antitumor growth-inhibiting effect on prostate and lung tumors in nude mice with xenografts of A549 and PC3 [1].
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
SZL-P1-41 is a chromone that is 3-(1,3-benzothiazol-2-yl)-8-(1-piperidinylmethyl)chromen-4-one bearing additional ethyl and hydroxy substituents at positions 6 and 7 respectively. It has a role as an antineoplastic agent and an EC 6.3.2.19 (ubiquitin--protein ligase) inhibitor. It is a member of benzothiazoles, a member of chromones, a member of piperidines and a member of phenols.
|
| Molecular Formula |
C24H24N2O3S
|
|
|---|---|---|
| Molecular Weight |
420.52
|
|
| Exact Mass |
420.15
|
|
| Elemental Analysis |
C, 68.55; H, 5.75; N, 6.66; O, 11.41; S, 7.62
|
|
| CAS # |
222716-34-9
|
|
| Related CAS # |
|
|
| PubChem CID |
1286902
|
|
| Appearance |
Off-white to pink solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
610.0±65.0 °C at 760 mmHg
|
|
| Flash Point |
322.7±34.3 °C
|
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
|
| Index of Refraction |
1.687
|
|
| LogP |
4.85
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
30
|
|
| Complexity |
665
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S1C2=C([H])C([H])=C([H])C([H])=C2N=C1C1=C([H])OC2=C(C1=O)C([H])=C(C([H])([H])C([H])([H])[H])C(=C2C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])O[H]
|
|
| InChi Key |
JKIXLEKBXHMXTN-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C24H24N2O3S/c1-2-15-12-16-22(28)18(24-25-19-8-4-5-9-20(19)30-24)14-29-23(16)17(21(15)27)13-26-10-6-3-7-11-26/h4-5,8-9,12,14,27H,2-3,6-7,10-11,13H2,1H3
|
|
| Chemical Name |
3-(2-Benzothiazolyl)-6-ethyl-7-hydroxy-8-(1-piperidinylmethyl)-4H-1-benzopyran-4-one
|
|
| Synonyms |
SZL-P1-41; SZL P1 41; SZLP141; SKP2 E3 Ligase Inhibitor III; SZLP-141; SZLP 141;
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 2.5~5 mg/mL ( 5.95~11.89 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (11.89 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3780 mL | 11.8900 mL | 23.7801 mL | |
| 5 mM | 0.4756 mL | 2.3780 mL | 4.7560 mL | |
| 10 mM | 0.2378 mL | 1.1890 mL | 2.3780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
